{"id":"sti-1558","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"STI-1558 works by inhibiting the SGLT2 receptor, which is involved in glucose reabsorption in the kidneys. This leads to increased glucose excretion in the urine and decreased glucose levels in the blood. By targeting SGLT2, STI-1558 aims to improve glycemic control in patients with diabetes.","oneSentence":"STI-1558 is a small molecule drug that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:37.229Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05716425","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of STI-1558 in Adult Subjects With Mild or Moderate (COVID-19)","status":"COMPLETED","sponsor":"Zhejiang ACEA Pharmaceutical Co. Ltd.","startDate":"2023-02-08","conditions":"COVID-19","enrollment":1218},{"nctId":"NCT06044233","phase":"PHASE1","title":"A Bioequivalence Trial of Fasting Single Oral STI-1558 Capsule in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"Zhejiang ACEA Pharmaceutical Co. Ltd.","startDate":"2023-09-28","conditions":"COVID-19","enrollment":32},{"nctId":"NCT05754411","phase":"PHASE1","title":"[14C] Study on Mass Balance and Biotransformation of STI-1558 in Healthy Chinese Adult Male Subjects","status":"COMPLETED","sponsor":"Zhejiang ACEA Pharmaceutical Co. Ltd.","startDate":"2023-05-15","conditions":"COVID-19","enrollment":6},{"nctId":"NCT05685719","phase":"PHASE1","title":"A Study to Evaluate the Relative Bioavailability of STI-1558 and the Effect of Itraconazole and Rifampin on the Pharmacokinetics of STI-1558","status":"COMPLETED","sponsor":"Zhejiang ACEA Pharmaceutical Co. Ltd.","startDate":"2023-01-04","conditions":"COVID-19 Pneumonia","enrollment":37},{"nctId":"NCT05523739","phase":"PHASE1","title":"Safety and Efficacy Study of STI-1558 in Healthy Adults and SARS-CoV-2-Positive Patients","status":"COMPLETED","sponsor":"Zhejiang ACEA Pharmaceutical Co. Ltd.","startDate":"2022-09-16","conditions":"SARS-CoV-2 Infection","enrollment":79},{"nctId":"NCT05364840","phase":"PHASE1","title":"Study to Assess the Safety, Tolerability and Pharmacokinetics of STI-1558 in Healthy Volunteers","status":"COMPLETED","sponsor":"Sorrento Therapeutics, Inc.","startDate":"2022-06-07","conditions":"COVID-19","enrollment":58}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro)."],"phase":"phase_3","status":"active","brandName":"STI-1558","genericName":"STI-1558","companyName":"Zhejiang ACEA Pharmaceutical Co. Ltd.","companyId":"zhejiang-acea-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"STI-1558 is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}